ITMI20010009A1 - Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera - Google Patents

Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera Download PDF

Info

Publication number
ITMI20010009A1
ITMI20010009A1 IT2001MI000009A ITMI20010009A ITMI20010009A1 IT MI20010009 A1 ITMI20010009 A1 IT MI20010009A1 IT 2001MI000009 A IT2001MI000009 A IT 2001MI000009A IT MI20010009 A ITMI20010009 A IT MI20010009A IT MI20010009 A1 ITMI20010009 A1 IT MI20010009A1
Authority
IT
Italy
Prior art keywords
brivudine
treatment
patients
magnesium stearate
aciclovir
Prior art date
Application number
IT2001MI000009A
Other languages
English (en)
Italian (it)
Inventor
Alessandro Casini
Bettina Stubinski
Attilio Crea
Original Assignee
Menarini Ricerche Spa
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITMI20010009A0 publication Critical patent/ITMI20010009A0/it
Priority to IT2001MI000009A priority Critical patent/ITMI20010009A1/it
Application filed by Menarini Ricerche Spa, Berlin Chemie Ag filed Critical Menarini Ricerche Spa
Priority to IE20010413A priority patent/IE20010413A1/en
Priority to GB0110682A priority patent/GB2370771A/en
Priority to HR20010345A priority patent/HRPK20010345B3/xx
Priority to CH00987/01A priority patent/CH695662A5/de
Priority to SE0102309A priority patent/SE0102309L/
Priority to DKPA200101019A priority patent/DK177084B1/da
Priority to FR0108596A priority patent/FR2818907B1/fr
Priority to NL1018431A priority patent/NL1018431C2/nl
Priority to FI20011446A priority patent/FI20011446A7/fi
Priority to CZ20012464A priority patent/CZ20012464A3/cs
Priority to BE2001/0452A priority patent/BE1014522A5/fr
Priority to UA2001074658A priority patent/UA76402C2/uk
Priority to SK957-2001A priority patent/SK287043B6/sk
Priority to GR20010100322A priority patent/GR1004012B/el
Priority to ES200101566A priority patent/ES2192456B1/es
Priority to PL01348480A priority patent/PL348480A1/xx
Priority to PT102642A priority patent/PT102642B/pt
Priority to HU0102816A priority patent/HUP0102816A3/hu
Priority to AT0805702U priority patent/AT6141U1/de
Publication of ITMI20010009A1 publication Critical patent/ITMI20010009A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IT2001MI000009A 2001-01-03 2001-01-03 Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera ITMI20010009A1 (it)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IT2001MI000009A ITMI20010009A1 (it) 2001-01-03 2001-01-03 Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
IE20010413A IE20010413A1 (en) 2001-01-03 2001-04-25 Once-a-day pharmaceutical composition containing Brivudine
GB0110682A GB2370771A (en) 2001-01-03 2001-05-01 Once-a-day pharmaceutical composition comprising brivudine
HR20010345A HRPK20010345B3 (en) 2001-01-03 2001-05-11 Pharmaceutical preparation containing brivudin to be administered once a day
CH00987/01A CH695662A5 (de) 2001-01-03 2001-05-29 Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichungn.
SE0102309A SE0102309L (sv) 2001-01-03 2001-06-28 Farmaceutisk engång-om-dagen-komposition innehållande brivudin
DKPA200101019A DK177084B1 (da) 2001-01-03 2001-06-29 Farmaceutisk præparat indeholdende brivudin til indgivelse én gang dagligt
FR0108596A FR2818907B1 (fr) 2001-01-03 2001-06-29 Utilisation de la brivudine pour la preparation d'une composition pharmaceutique
NL1018431A NL1018431C2 (nl) 2001-01-03 2001-07-02 EÚnmaal daags farmaceutische samenstelling die brivudine bevat.
FI20011446A FI20011446A7 (fi) 2001-01-03 2001-07-03 Farmaseuttinen, brivudiinia sisältävä, kerran päivässä käytettävä koostumus
SK957-2001A SK287043B6 (sk) 2001-01-03 2001-07-04 Použitie brivudínu na liečenie infekcií herpes alebo post-herpetickej neuralgie
CZ20012464A CZ20012464A3 (cs) 2001-01-03 2001-07-04 Farmaceutický prostředek
BE2001/0452A BE1014522A5 (fr) 2001-01-03 2001-07-04 Composition pharmaceutique et son utilisation.
UA2001074658A UA76402C2 (en) 2001-01-03 2001-07-04 Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia
GR20010100322A GR1004012B (el) 2001-01-03 2001-07-05 Απαξ ημερησιως χορηγουμενη φαρμακευτικη συνθεση που εμπεριεχει βριβουδινη
ES200101566A ES2192456B1 (es) 2001-01-03 2001-07-05 Composicion farmaceutica de una vez al dia que contiene brivudina.
PL01348480A PL348480A1 (en) 2001-01-03 2001-07-05 Brivudine containing pharmacological compositions to be administered once a day
PT102642A PT102642B (pt) 2001-01-03 2001-07-05 Composicao farmaceutica de dosagem unica diaria contendo brivudine
HU0102816A HUP0102816A3 (en) 2001-01-03 2001-07-05 Pharmaceutical composition containg brivudine
AT0805702U AT6141U1 (de) 2001-01-03 2002-07-03 Brivudin enthaltende pharmazeutische zusammensetzung für die einmal tägliche verabreichung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI000009A ITMI20010009A1 (it) 2001-01-03 2001-01-03 Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera

Publications (2)

Publication Number Publication Date
ITMI20010009A0 ITMI20010009A0 (it) 2001-01-03
ITMI20010009A1 true ITMI20010009A1 (it) 2002-07-03

Family

ID=11446384

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2001MI000009A ITMI20010009A1 (it) 2001-01-03 2001-01-03 Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera

Country Status (20)

Country Link
AT (1) AT6141U1 (fr)
BE (1) BE1014522A5 (fr)
CH (1) CH695662A5 (fr)
CZ (1) CZ20012464A3 (fr)
DK (1) DK177084B1 (fr)
ES (1) ES2192456B1 (fr)
FI (1) FI20011446A7 (fr)
FR (1) FR2818907B1 (fr)
GB (1) GB2370771A (fr)
GR (1) GR1004012B (fr)
HR (1) HRPK20010345B3 (fr)
HU (1) HUP0102816A3 (fr)
IE (1) IE20010413A1 (fr)
IT (1) ITMI20010009A1 (fr)
NL (1) NL1018431C2 (fr)
PL (1) PL348480A1 (fr)
PT (1) PT102642B (fr)
SE (1) SE0102309L (fr)
SK (1) SK287043B6 (fr)
UA (1) UA76402C2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239527B1 (es) * 2004-03-01 2006-11-16 M. Cruz Fernandez Gonzalez Composicion farmacologica de uso topico para el tratamiento del herpes zoster.
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0104857A1 (fr) * 1982-09-28 1984-04-04 Beecham Group Plc Dérivés de la déoxyuridine, leurs méthodes de préparation et leur emploi en médecine
IT1170232B (it) * 1983-10-31 1987-06-03 Anna Gioia Stendardi Composizioni terapeutiche ad attivita' antivirale
US5446031A (en) * 1991-04-24 1995-08-29 Yamasa Shuyu Kabushiki Kaisha 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives
CA2243237C (fr) * 1996-01-19 2008-09-02 Glaxo Group Limited Utilisation de valaciclovir dans la fabrication d'un medicament destine au traitement de l'herpes genital

Also Published As

Publication number Publication date
CH695662A5 (de) 2006-07-31
FI20011446L (fi) 2002-07-04
CZ20012464A3 (cs) 2002-08-14
FR2818907A1 (fr) 2002-07-05
ES2192456B1 (es) 2005-02-01
GB0110682D0 (en) 2001-06-20
HRP20010345A2 (en) 2003-08-31
IE20010413A1 (en) 2003-04-16
PL348480A1 (en) 2002-07-15
AT6141U1 (de) 2003-05-26
HRPK20010345B3 (en) 2005-02-28
FI20011446A7 (fi) 2002-07-04
DK177084B1 (da) 2011-07-11
GR1004012B (el) 2002-11-01
FI20011446A0 (fi) 2001-07-03
GR20010100322A (el) 2002-10-08
FR2818907B1 (fr) 2006-05-26
DK200101019A (da) 2002-07-04
SK9572001A3 (en) 2003-03-04
HUP0102816A3 (en) 2005-01-28
ITMI20010009A0 (it) 2001-01-03
UA76402C2 (en) 2006-08-15
HU0102816D0 (en) 2001-09-28
PT102642A (pt) 2002-07-31
BE1014522A5 (fr) 2003-12-02
ES2192456A1 (es) 2003-10-01
SK287043B6 (sk) 2009-10-07
NL1018431C2 (nl) 2002-07-05
GB2370771A (en) 2002-07-10
PT102642B (pt) 2003-06-30
HUP0102816A2 (en) 2002-10-28
SE0102309D0 (sv) 2001-06-28
SE0102309L (sv) 2002-07-04

Similar Documents

Publication Publication Date Title
AU2013336491B2 (en) Pharmaceutical antiretroviral composition
IT9021833A1 (it) Composizioni farmaceutiche comprendenti associazioni fra sali di s-adenosil-l-metionina e acido 5-metil (o 5-formil)-tetraidrofolico per la terapia di complicanze neurologiche negli ammalati di aids.
US20150104511A1 (en) Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
CA2633603A1 (fr) Combinaison pharmaceutique
US20140193491A1 (en) Pharmaceutical antiretroviral composition
JP2022550828A (ja) カボテグラビルおよびリルピビリンでｈｉｖを治療するための方法
ITMI20010009A1 (it) Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
Hardenia et al. Formulation and optimization of fast dissolving tablets of promethazine theoclate using 32 factorial design
King et al. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children
RU2842683C1 (ru) Фармацевтическая комбинация осельтамивира, парацетамола, источника витамина с и блокатора гистаминовых рецепторов
Ekmekyapar et al. Antiviral drugs and their toxicities
WO2023091107A1 (fr) Préparation de nouvelles formulations médicamenteuses capables de présenter un effet antiviral et investigation de leur effet contre la covid-19
SI20854A (sl) Farmacevtska zmes z učinkovino Brivudine z enkratnim dnevnim doziranjem
Crauwels et al. Absence of a pharmacokinetic interaction of rilpivirine with the P‐glycoprotein substrate digoxin in healthy volunteers
JP2009507850A5 (fr)
RU2008108216A (ru) Фармацевтические дозированные формы и составы, содержащие лекозотан
Sabo et al. Lack of a pharmacokinetic effect between steady-state tipranavir/ritonavir (TPV/r) and single-dose valacyclovir in healthy volunteers
EA005497B1 (ru) Применение фармацевтической композиции, содержащей бривудин, для лечения герпесвирусных инфекций
WO2022118020A1 (fr) Méthode de traitement d'une infection virale
WO2021057661A1 (fr) Composition pharmaceutique pour diminuer la glycémie
Arends Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
IL26469A (en) Synergistic pharmaceutical composition containing sulphamethopyrazine and pyrimethamine having antimalarial action